Treatment of tinnitus

Reading File

Finding Sources

Searching PubMed

tinnitus treatment management

Searching the Web

tinnitus treatment guidelines 2025 2026

Reading File

Reading Article

Finding Sources

Reading Article

Reading File

I now have comprehensive information from multiple sources. Let me compile the full answer.

Treatment of Tinnitus

Tinnitus - the perception of sound without an external source - affects an estimated 50 million US adults. There is no universal cure, but multiple management strategies can reduce distress and improve quality of life. Treatment is guided by tinnitus type (subjective vs. objective, pulsatile vs. non-pulsatile) and by severity.

Step 1: Address Underlying Causes First

Before any specific therapy, identify and eliminate reversible causes:

Ototoxic drugs: Aspirin, NSAIDs, aminoglycosides, loop diuretics, TCAs, oral contraceptives, cocaine - review and adjust the medication list
Benzodiazepine withdrawal is itself a known cause of tinnitus
Middle/outer ear pathology: Cerumen impaction, otosclerosis, Meniere disease
Metabolic causes: Hyperthyroidism, hyperlipidemia, vitamin deficiencies, anemia
Vascular causes: Pulsatile tinnitus requires MRA/CT to rule out AVM, carotid stenosis, glomus tumor
Hearing loss: Correcting it (surgically or with aids) often reduces tinnitus burden

Patients should also be counseled to avoid caffeine and nicotine, which are aggravating factors.

1. Sound-Based Therapies

Hearing Aids

When coexisting sensorineural hearing loss (SNHL) is present, hearing aids are first-line. Amplifying environmental sound reduces the contrast that makes tinnitus more noticeable. Note: occlusive hearing aids that act as earplugs can worsen tinnitus.

Sound Masking / White Noise Generators

Bedside sound generators or wearable masking devices provide background noise that reduces perception of tinnitus. Evidence supports short-term benefit, though long-term masking alone has limited efficacy compared to combined approaches.

A 2024 network meta-analysis (Lu et al., PMID 38788246) including 2,354 patients found that sound therapy ranked first for reducing Tinnitus Handicap Inventory (THI) scores (86.9% probability of being best), and was also most effective for reducing perceived loudness.

2. Tinnitus Retraining Therapy (TRT)

TRT was developed by Jastreboff and combines:

Directive counseling - demystifying tinnitus, explaining the neurophysiological model, removing the emotional threat response
Low-level broadband sound stimulation - worn chronically to reduce the contrast between tinnitus and background sound, facilitating habituation

TRT is grouped by severity into categories (0-4), with different protocols for each. Multiple controlled studies show it achieves habituation in 70-80% of patients after 12-24 months. It is also effective for hyperacusis (sound sensitivity that frequently coexists with tinnitus) and for somatosounds (pulsatile tinnitus).

Shambaugh Surgery of the Ear, p. 322-323

3. Psychological / Behavioral Therapies

Cognitive Behavioral Therapy (CBT)

CBT is the best-validated psychological treatment for tinnitus and the most widely recommended by guidelines:

Targets distorted negative cognitions about tinnitus ("this will drive me mad") and avoidance behaviors
Typically 6-10 weekly sessions; skills can be self-applied afterward
Multiple Cochrane reviews confirm: CBT significantly reduces tinnitus-related distress (effect sizes 0.44-0.91) and improves mood, though it does not reduce tinnitus loudness
Can be delivered individually, in groups, or via internet-based platforms

The 2024 network meta-analysis found CBT ranked first for reducing tinnitus distress (VAS-Distress: 84.7% probability of best) and first for Tinnitus Questionnaire (TQ) scores (89.5%).

Acceptance and Commitment Therapy (ACT)

ACT was the top-ranked treatment for anxiety/depression and insomnia comorbid to tinnitus in the same meta-analysis (82.4% and 83.2% respectively). It teaches psychological flexibility and non-judgmental acceptance of tinnitus rather than fighting it.

Mindfulness-Based Therapy

Emerging positive data, currently considered adjunctive.

4. Pharmacotherapy

No drug is FDA-approved specifically for tinnitus. Medications are used to manage tinnitus-related comorbidities (anxiety, depression, insomnia) or have shown modest signal in trials.

A 2025 network meta-analysis of 60 RCTs (Li et al., PMID 40441764) found:

Ginkgo biloba + vitamin - ranked first for reducing tinnitus severity (SMD -3.11); however certainty of evidence was very low by GRADE
Acamprosate (GABA agonist) - ranked first for reducing annoyance (SMD -0.88)
Fluoxetine - ranked first for reducing perceived loudness (SMD -3.28)
Overall evidence quality was poor, limiting clinical translation

Antidepressants

Sertraline: One SSRI with consistent data - reduced severity, loudness, anxiety and depression in a double-blind RCT; considered if depression/anxiety are prominent
Nortriptyline: RCT showed 67% reported subjective benefit vs. 40% placebo; however tinnitus severity was not statistically different between groups
The AAO-HNS 2014 guideline advises against routinely prescribing antidepressants or anxiolytics solely for tinnitus without comorbid psychiatric indications

Benzodiazepines

Not recommended as a first-line or long-term treatment
Alprazolam RCT: 76% reduction in loudness vs. 5% placebo, but study had methodological flaws
Risk of dependence, rebound tinnitus on withdrawal, and - importantly - they impair neural plasticity, making them counterproductive to TRT and CBT
May worsen long-term habituation

Other agents

Melatonin: May help sleep disturbance in tinnitus patients; does not modify tinnitus severity
Ginkgo biloba alone (without vitamin): Earlier systematic reviews found no significant benefit; newer data (with added vitamins) is more promising but low certainty
Antioxidant vitamins: Uncontrolled trials suggest benefit; not confirmed in RCTs
Anticonvulsants, intratympanic medications: Advised against by current guidelines

5. Neuromodulation (Emerging)

Repetitive Transcranial Magnetic Stimulation (rTMS): Targets the auditory cortex; some positive RCT data, included in recent network meta-analyses with modest effect
Transcranial Direct Current Stimulation (tDCS): Investigational
Bimodal stimulation (combined sound + somatosensory/electrical): Lenire device received FDA clearance in 2023 for chronic tinnitus; shows benefit in blinded RCTs

6. Surgical Treatment

Surgery plays a role in secondary (treatable cause) tinnitus only:

Stapedectomy for otosclerosis
Tumor resection (acoustic neuroma, glomus jugulare)
Carotid endarterectomy or vascular repair for arterial pulsatile tinnitus
Cochlear implantation in cases of profound SNHL - often dramatically reduces tinnitus

Medication or surgery helps in < 1% of all tinnitus cases (Shambaugh).

7. Management Algorithm (Summary)

Severity	First-line Approach
Mild, non-bothersome	Reassurance, lifestyle modification (avoid caffeine/nicotine), address hearing loss
Moderate, bothersome	Hearing aids (if SNHL), sound therapy, TRT or CBT
Severe, distressing	Combination: sound therapy + CBT or TRT; treat anxiety/depression; consider rTMS
Secondary (identifiable cause)	Treat the cause

Recent Guideline Highlights

The 2025 VA/DOD Clinical Practice Guideline (Sherlock et al., PMID 40111327) - the first dedicated federal CPG for tinnitus - emphasizes:

Evidence-based education and self-management strategies
Recommended outcome measures (THI, TQ, functional status) to track effectiveness
Substantial knowledge gaps remain, requiring further research

The AAO-HNS 2014 guideline (still the main ENT society guideline) recommends against: antidepressants, anxiolytics, anticonvulsants, dietary supplements, and intratympanic medications as primary treatments for bothersome tinnitus.

Sources:

Textbook of Family Medicine 9e (Rakel), p. 18
Cummings Otolaryngology Head and Neck Surgery
Shambaugh Surgery of the Ear, pp. 322-325
Scott-Brown's Otorhinolaryngology Head & Neck Surgery Vol 2
Lu et al., 2024 - Non-invasive treatments in chronic tinnitus, network meta-analysis PMID 38788246
Sherlock et al., 2025 - VA/DOD CPG for Tinnitus PMID 40111327
Li et al., 2025 - Pharmacotherapy for tinnitus, network meta-analysis PMID 40441764

This is a shared conversation. Sign in to Orris to start your own chat.